AroCell AB (AROC) - Total Liabilities
Based on the latest financial reports, AroCell AB (AROC) has total liabilities worth Skr14.01 Million SEK (≈ $1.51 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AroCell AB - Total Liabilities Trend (2007–2024)
This chart illustrates how AroCell AB's total liabilities have evolved over time, based on quarterly financial data. See how liquid is AroCell AB's working capital to evaluate short-term liquidity relative to the company's equity base.
AroCell AB Competitors by Total Liabilities
The table below lists competitors of AroCell AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BioLineRx Ltd
NASDAQ:BLRX
|
USA | $17.56 Million |
|
Thanasiri Group Public Company Limited
BK:THANA
|
Thailand | ฿579.66 Million |
|
Sarama Resource
V:SWA
|
Canada | CA$1.78 Million |
|
Lexaria Bioscience Corp
NASDAQ:LEXX
|
USA | $277.00K |
|
Imexhs Ltd
AU:IME
|
Australia | AU$8.36 Million |
|
Melbana Energy Ltd
AU:MAY
|
Australia | AU$24.24 Million |
|
Young Heung I&
KO:012160
|
Korea | ₩235.50 Billion |
|
Mynd.ai, Inc.
NYSE MKT:MYND
|
USA | $203.97 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down AroCell AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AroCell AB (AROC) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AroCell AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AroCell AB (2007–2024)
The table below shows the annual total liabilities of AroCell AB from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr12.93 Million ≈ $1.39 Million |
+14.96% |
| 2023-12-31 | Skr11.25 Million ≈ $1.21 Million |
-15.56% |
| 2022-12-31 | Skr13.32 Million ≈ $1.43 Million |
+33.71% |
| 2021-12-31 | Skr9.96 Million ≈ $1.07 Million |
+136.21% |
| 2020-12-31 | Skr4.22 Million ≈ $453.82K |
-61.55% |
| 2019-12-31 | Skr10.97 Million ≈ $1.18 Million |
+277.58% |
| 2018-12-31 | Skr2.90 Million ≈ $312.62K |
+2.44% |
| 2017-12-31 | Skr2.84 Million ≈ $305.18K |
-4.37% |
| 2016-12-31 | Skr2.97 Million ≈ $319.13K |
+81.72% |
| 2015-12-31 | Skr1.63 Million ≈ $175.61K |
-43.38% |
| 2014-12-31 | Skr2.88 Million ≈ $310.18K |
+26.74% |
| 2013-12-31 | Skr2.27 Million ≈ $244.74K |
+24.27% |
| 2012-12-31 | Skr1.83 Million ≈ $196.94K |
-17.52% |
| 2011-12-31 | Skr2.22 Million ≈ $238.76K |
-8.88% |
| 2010-12-31 | Skr2.43 Million ≈ $262.04K |
-18.89% |
| 2009-12-31 | Skr3.00 Million ≈ $323.06K |
+312.36% |
| 2008-12-31 | Skr728.00K ≈ $78.34K |
+31.88% |
| 2007-12-31 | Skr552.00K ≈ $59.40K |
-- |
About AroCell AB
AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB… Read more